6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02967250 (ClinicalTrials.gov)	April 1, 2020	13/9/2016	Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Respons ...	Parkinson Disease	Drug: ursodeoxycholic acid	University of Minnesota	NULL	Not yet recruiting	18 Years	N/A	All	20	Phase 1	United States
2	NCT03840005 (ClinicalTrials.gov)	December 18, 2018	11/2/2019	Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The UP Study	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tol ...	Parkinson's Disease	Drug: Ursonorm	Sheffield Teaching Hospitals NHS Foundation Trust	JP Moulton Charitable Foundation;PRO.MED.CS Praha a.s.;Clinical Trials Research Unit, University of ...	Completed	18 Years	75 Years	All	31	Phase 2	United Kingdom
3	EUCTR2018-001887-46-GB (EUCTR)	08/11/2018	19/06/2019	Trial of Ursodeoxycholic Acid (UDCA) for PD. The 'UP-study'	A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tol ...	Parkinson’s disease (PD) MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson ...	Trade Name: Ursonorm Product Name: Ursonorm INN or Proposed INN: Ursodeoxycholic acid	Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom

First Previous1Next Last